Nascent Biotech Stock Book Value Per Share
| NBIO Stock | USD 0.06 0.0002 0.32% |
Nascent Biotech fundamentals help investors to digest information that contributes to Nascent Biotech's financial success or failures. It also enables traders to predict the movement of Nascent OTC Stock. The fundamental analysis module provides a way to measure Nascent Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nascent Biotech otc stock.
Nascent |
Nascent Biotech OTC Stock Book Value Per Share Analysis
Nascent Biotech's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Nascent Biotech Book Value Per Share | (0.01) X |
Most of Nascent Biotech's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nascent Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of Nascent Biotech is about -0.01 times. This is 99.41% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The book value per share for all United States stocks is 100.0% higher than that of the company.
Nascent Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nascent Biotech's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Nascent Biotech could also be used in its relative valuation, which is a method of valuing Nascent Biotech by comparing valuation metrics of similar companies.Nascent Biotech is currently under evaluation in book value per share category among its peers.
Nascent Fundamentals
| Return On Asset | -0.88 | |||
| Profit Margin | (1.25) % | |||
| Operating Margin | (0.92) % | |||
| Current Valuation | 21.83 M | |||
| Shares Outstanding | 119.56 M | |||
| Shares Owned By Insiders | 31.85 % | |||
| Shares Owned By Institutions | 0.80 % | |||
| Price To Earning | 66.00 X | |||
| Price To Book | 6.91 X | |||
| Price To Sales | 21.78 X | |||
| Revenue | 1000 K | |||
| Gross Profit | 1000 K | |||
| EBITDA | (134.37 K) | |||
| Net Income | (470.39 K) | |||
| Cash And Equivalents | 145.57 K | |||
| Total Debt | 64.89 K | |||
| Debt To Equity | (1.89) % | |||
| Current Ratio | 0.11 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | 413.48 K | |||
| Earnings Per Share | (0) X | |||
| Beta | -3.14 | |||
| Market Capitalization | 10.76 M | |||
| Total Asset | 105.41 K | |||
| Retained Earnings | (17.28 M) | |||
| Working Capital | 383 K | |||
| Current Asset | 522 K | |||
| Current Liabilities | 139 K | |||
| Net Asset | 105.41 K |
About Nascent Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nascent Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nascent Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nascent Biotech based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Nascent Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nascent Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nascent Biotech will appreciate offsetting losses from the drop in the long position's value.Moving against Nascent OTC Stock
| 0.63 | REGN | Regeneron Pharmaceuticals | PairCorr |
| 0.62 | NVO | Novo Nordisk AS | PairCorr |
| 0.62 | NONOF | Novo Nordisk AS | PairCorr |
| 0.57 | QSAM | Qsam Biosciences | PairCorr |
| 0.45 | CSLLY | CSL | PairCorr |
The ability to find closely correlated positions to Nascent Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nascent Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nascent Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nascent Biotech to buy it.
The correlation of Nascent Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nascent Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nascent Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nascent Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Nascent OTC Stock
Nascent Biotech financial ratios help investors to determine whether Nascent OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nascent with respect to the benefits of owning Nascent Biotech security.